MX395534B - Inhibidores de demetilasa-1 especifica de lisina. - Google Patents
Inhibidores de demetilasa-1 especifica de lisina.Info
- Publication number
- MX395534B MX395534B MX2020010900A MX2020010900A MX395534B MX 395534 B MX395534 B MX 395534B MX 2020010900 A MX2020010900 A MX 2020010900A MX 2020010900 A MX2020010900 A MX 2020010900A MX 395534 B MX395534 B MX 395534B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- compositions
- compounds
- lysine
- specific demethylase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Polyamides (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462020886P | 2014-07-03 | 2014-07-03 | |
| PCT/US2015/038345 WO2016003917A1 (en) | 2014-07-03 | 2015-06-29 | Inhibitors of lysine specific demethylase-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020010900A MX2020010900A (es) | 2022-09-13 |
| MX395534B true MX395534B (es) | 2025-03-25 |
Family
ID=55019883
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010900A MX395534B (es) | 2014-07-03 | 2015-06-29 | Inhibidores de demetilasa-1 especifica de lisina. |
| MX2017000168A MX376207B (es) | 2014-07-03 | 2015-06-29 | Inhibidores de demetilasa-1 especifica de lisina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000168A MX376207B (es) | 2014-07-03 | 2015-06-29 | Inhibidores de demetilasa-1 especifica de lisina. |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US9902719B2 (OSRAM) |
| EP (2) | EP3511319B1 (OSRAM) |
| JP (2) | JP6663866B2 (OSRAM) |
| KR (1) | KR102475498B1 (OSRAM) |
| CN (2) | CN106795103B (OSRAM) |
| AU (1) | AU2015284383B2 (OSRAM) |
| BR (1) | BR112017000043A2 (OSRAM) |
| CA (1) | CA2954049A1 (OSRAM) |
| CL (1) | CL2016003422A1 (OSRAM) |
| CO (1) | CO2017000549A2 (OSRAM) |
| CY (1) | CY1125127T1 (OSRAM) |
| DK (2) | DK3511319T3 (OSRAM) |
| EA (2) | EA201891526A3 (OSRAM) |
| EC (1) | ECSP17006821A (OSRAM) |
| ES (2) | ES2907676T3 (OSRAM) |
| FI (1) | FI3511319T3 (OSRAM) |
| HR (2) | HRP20220414T1 (OSRAM) |
| HU (2) | HUE058852T2 (OSRAM) |
| IL (2) | IL249881B (OSRAM) |
| LT (2) | LT3511319T (OSRAM) |
| MX (2) | MX395534B (OSRAM) |
| PL (2) | PL3511319T3 (OSRAM) |
| PT (2) | PT3511319T (OSRAM) |
| RS (2) | RS64423B1 (OSRAM) |
| SA (1) | SA517380651B1 (OSRAM) |
| SG (2) | SG11201610975RA (OSRAM) |
| SI (2) | SI3511319T1 (OSRAM) |
| SM (2) | SMT202300205T1 (OSRAM) |
| WO (1) | WO2016003917A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201911989SA (en) | 2015-06-12 | 2020-02-27 | Oryzon Genomics Sa | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| CN109195593A (zh) | 2016-03-15 | 2019-01-11 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| ES3042059T3 (en) | 2016-03-16 | 2025-11-18 | Oryzon Genomics Sa | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US20190256930A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| DK3661510T3 (da) | 2017-08-03 | 2025-01-02 | Oryzon Genomics Sa | Fremgangsmåder til behandling af adfærdsændringer |
| MX2021001608A (es) * | 2018-08-10 | 2021-07-15 | Navire Pharma Inc | Inhibidores de ptpn11. |
| US12479845B2 (en) | 2019-02-01 | 2025-11-25 | Hanmi Pharm. Co., Ltd. | Imidazopyridine derivative compounds and use of same |
| EP3907225A4 (en) * | 2019-02-01 | 2022-09-14 | Hanmi Pharm. Co., Ltd. | COMPOUNDS DERIVED FROM IMIDAZOPYRIDINE AND THEIR USE |
| EP3941465B1 (en) | 2019-03-20 | 2025-09-17 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| CN121370879A (zh) | 2019-03-20 | 2026-01-23 | 奥莱松基因组股份有限公司 | 治疗边缘型人格障碍的方法 |
| WO2021004610A1 (en) | 2019-07-05 | 2021-01-14 | Oryzon Genomics, S.A. | Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors |
| US11360505B2 (en) | 2020-02-11 | 2022-06-14 | Simmonds Precision Products, Inc. | Distributed network time synchronization |
| CN114105950B (zh) * | 2020-08-31 | 2022-09-06 | 南京明德新药研发有限公司 | 吡唑类化合物及其应用 |
| TWI834127B (zh) * | 2021-03-11 | 2024-03-01 | 大陸商南京明德新藥研發有限公司 | 噻吩類化合物及其應用 |
| US20240216357A1 (en) * | 2021-03-24 | 2024-07-04 | Sichuan Huiyu Pharmaceutical Co., Ltd. | Polycyclic compound and application thereof |
| BR112023020554A2 (pt) | 2021-04-08 | 2023-12-05 | Oryzon Genomics Sa | Combinações de inibidores de lsd1 para o tratamento de cânceres mieloides |
| CN116102533A (zh) * | 2021-11-11 | 2023-05-12 | 中国科学院上海药物研究所 | 一种芳杂环类化合物及其应用 |
| CN119497613A (zh) | 2022-05-09 | 2025-02-21 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗nf1-突变肿瘤的方法 |
| JP2025516647A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法 |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1963188A1 (de) * | 1969-12-17 | 1971-06-24 | Bayer Ag | Neue Cyanphenyl-1,4-dihydropyridinderivate |
| AU2002214546A1 (en) * | 2000-09-29 | 2002-04-08 | Cor Therapeutics, Inc. | Bicyclic pyrimidin-4-one based inhibitors of factor xa |
| US7365069B2 (en) * | 2002-04-10 | 2008-04-29 | Bexel Pharmaceuticals Inc. | Pyrimidone derivatives |
| JP2005170792A (ja) * | 2002-11-22 | 2005-06-30 | Mitsubishi Pharma Corp | Ｌ−プロリン誘導体およびその医薬としての用途。 |
| CA2548918C (en) * | 2003-12-11 | 2013-05-21 | Mitsubishi Pharma Corporation | Alpha-amino acid derivatives and use thereof as medicines |
| WO2006073167A1 (ja) * | 2005-01-07 | 2006-07-13 | Ono Pharmaceutical Co., Ltd. | ピロリジン誘導体 |
| PL372332A1 (pl) * | 2005-01-19 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
| WO2006129181A2 (en) * | 2005-06-03 | 2006-12-07 | Orchid Research Laboratories Limited | Preparation of 4-pyrimidone derivatives for treating inflammatory diseases |
| AU2006287202B2 (en) * | 2005-09-01 | 2013-01-24 | Eli Lilly And Company | 6-arylalkylamino- 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2c receptor agonists |
| JP2007197324A (ja) * | 2006-01-23 | 2007-08-09 | Toray Ind Inc | ２，４，５−置換−１，３−アゾール誘導体 |
| WO2008021309A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Imidazolidin-2-one derivatives useful as pr modulators |
| TW200815428A (en) * | 2006-08-15 | 2008-04-01 | Wyeth Corp | Oxazolidone derivatives as PR modulators |
| PE20081803A1 (es) | 2007-03-09 | 2008-12-11 | Wyeth Corp | Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo |
| CL2008002793A1 (es) * | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| WO2009132310A1 (en) * | 2008-04-25 | 2009-10-29 | Wisconsin Alumni Research Foundation | Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth |
| US20130096160A1 (en) * | 2010-04-14 | 2013-04-18 | Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
| WO2012009475A1 (en) * | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| WO2013132380A1 (en) * | 2012-03-06 | 2013-09-12 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| SMT202300014T1 (it) * | 2013-12-11 | 2023-05-12 | Celgene Quanticel Research Inc | Inibitori della demetilasi lisina-specifica-1 |
| RU2016136091A (ru) * | 2014-02-14 | 2018-03-19 | Дзе Юниверсити Оф Бритиш Коламбиа | Соединения, воздействующие на днк-связывающий домен (dbd) андрогенового рецептора человека, в качестве терапевтических средств, а также способы их применения |
| AU2015253040B2 (en) * | 2014-05-01 | 2020-04-09 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| FR3020945B1 (fr) | 2014-05-16 | 2016-05-06 | Oreal | Composition pour colorer les fibres keratiniques comprenant une base d'oxydation et un coupleur heteroaryle particulier |
| HUE050564T2 (hu) * | 2014-06-27 | 2020-12-28 | Celgene Quanticel Res Inc | Lizinspecifikus demetiláz-1 inhibitorai |
| SG11201700007YA (en) * | 2014-07-03 | 2017-01-27 | Celgene Quanticel Res Inc | Inhibitors of lysine specific demethylase-1 |
-
2015
- 2015-06-29 SI SI201531948T patent/SI3511319T1/sl unknown
- 2015-06-29 SG SG11201610975RA patent/SG11201610975RA/en unknown
- 2015-06-29 RS RS20230452A patent/RS64423B1/sr unknown
- 2015-06-29 US US15/323,277 patent/US9902719B2/en active Active
- 2015-06-29 PL PL19156976.3T patent/PL3511319T3/pl unknown
- 2015-06-29 SM SM20230205T patent/SMT202300205T1/it unknown
- 2015-06-29 DK DK19156976.3T patent/DK3511319T3/da active
- 2015-06-29 AU AU2015284383A patent/AU2015284383B2/en not_active Ceased
- 2015-06-29 CN CN201580047448.1A patent/CN106795103B/zh not_active Expired - Fee Related
- 2015-06-29 EP EP19156976.3A patent/EP3511319B1/en active Active
- 2015-06-29 MX MX2020010900A patent/MX395534B/es unknown
- 2015-06-29 KR KR1020177003162A patent/KR102475498B1/ko active Active
- 2015-06-29 RS RS20220311A patent/RS63074B1/sr unknown
- 2015-06-29 CN CN201810425583.0A patent/CN108530424B/zh not_active Expired - Fee Related
- 2015-06-29 FI FIEP19156976.3T patent/FI3511319T3/fi active
- 2015-06-29 ES ES15814038T patent/ES2907676T3/es active Active
- 2015-06-29 PT PT191569763T patent/PT3511319T/pt unknown
- 2015-06-29 DK DK15814038.4T patent/DK3164380T3/da active
- 2015-06-29 EA EA201891526A patent/EA201891526A3/ru unknown
- 2015-06-29 LT LTEP19156976.3T patent/LT3511319T/lt unknown
- 2015-06-29 WO PCT/US2015/038345 patent/WO2016003917A1/en not_active Ceased
- 2015-06-29 EA EA201790085A patent/EA033698B1/ru not_active IP Right Cessation
- 2015-06-29 JP JP2016575768A patent/JP6663866B2/ja not_active Expired - Fee Related
- 2015-06-29 EP EP15814038.4A patent/EP3164380B1/en active Active
- 2015-06-29 PT PT158140384T patent/PT3164380T/pt unknown
- 2015-06-29 SM SM20220136T patent/SMT202200136T1/it unknown
- 2015-06-29 MX MX2017000168A patent/MX376207B/es active IP Right Grant
- 2015-06-29 PL PL15814038T patent/PL3164380T3/pl unknown
- 2015-06-29 HU HUE15814038A patent/HUE058852T2/hu unknown
- 2015-06-29 HU HUE19156976A patent/HUE062558T2/hu unknown
- 2015-06-29 LT LTEPPCT/US2015/038345T patent/LT3164380T/lt unknown
- 2015-06-29 SI SI201531797T patent/SI3164380T1/sl unknown
- 2015-06-29 SG SG10201802501RA patent/SG10201802501RA/en unknown
- 2015-06-29 CA CA2954049A patent/CA2954049A1/en not_active Abandoned
- 2015-06-29 BR BR112017000043-1A patent/BR112017000043A2/pt not_active Application Discontinuation
- 2015-06-29 ES ES19156976T patent/ES2948782T3/es active Active
- 2015-06-29 HR HRP20220414TT patent/HRP20220414T1/hr unknown
- 2015-06-29 HR HRP20230595TT patent/HRP20230595T1/hr unknown
-
2016
- 2016-12-30 CL CL2016003422A patent/CL2016003422A1/es unknown
-
2017
- 2017-01-01 IL IL249881A patent/IL249881B/en active IP Right Grant
- 2017-01-02 SA SA517380651A patent/SA517380651B1/ar unknown
- 2017-01-23 CO CONC2017/0000549A patent/CO2017000549A2/es unknown
- 2017-02-01 EC ECIEPI20176821A patent/ECSP17006821A/es unknown
-
2018
- 2018-01-10 US US15/867,397 patent/US10100046B2/en active Active
- 2018-09-05 US US16/122,703 patent/US20190002456A1/en not_active Abandoned
-
2019
- 2019-02-21 JP JP2019029856A patent/JP6768857B2/ja not_active Expired - Fee Related
-
2020
- 2020-01-19 IL IL272130A patent/IL272130B/en active IP Right Grant
-
2022
- 2022-04-11 CY CY20221100269T patent/CY1125127T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX381597B (es) | Inhibidores demetilasa-1 específica de lisina. | |
| MX376632B (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
| MX376207B (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
| MX376047B (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
| MX391865B (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
| MX373373B (es) | Inhibidores de desmetilasa-1 específica de lisina. | |
| MX375219B (es) | Inhibidores de histona demetilasa. | |
| SA515360657B1 (ar) | مثبطات ديميثيلاز هيستون | |
| MX2017003464A (es) | Inhibidores de histona desmetilasa. | |
| MX2017003466A (es) | Inhibidores de histona desmetilasa. | |
| MX2017003463A (es) | Inhibidores de histona desmetilasa. |